Table 1.
Univariate and multivariable analysis of survival in 1109 patients with primary myelofibrosis
| Overall survival | ||
|---|---|---|
| Variables | Univariate analysis P value (HR, 95%CI) | Multivariable analysis P value (HR, 95%CI) |
| Male | <0.0001 (1.3, 1.2–1.5) | |
| Age > 65 years | <0.0001 (2.4, 2–2.7) | <0.0001 (2, 1.6–2.7) |
| Degree of anemia | <0.0001 | 0.0001 |
| Severe anemia | 0.0001 (3.4, 2.7–4.3) | 0.0001 (2.5, 1.7–3.8) |
| Moderate anemia | 0.0001 (2.1, 1.6–2.8) | 0.02 (1.7, 1.1–2.8) |
| Mild anemia | 0.009 (1.4, 1.1–1.7) | 0.01(1.7, 1.1–2.5) |
| No anemia | Reference | Reference |
| Leukocytes >25 × 109/l | <0.0001 (2.2, 1.8–2.6) | 0.01 (1.5, 1.1–2) |
| Platelets <100 × 109/l | <0.0001(2, 1.7–2.4) | |
| Constitutional symptoms | <0.0001(1.8, 1.6–2) | 0.01 (1.4, 1.1–1.8) |
| Circulating blasts ≥ 1% | <0.0001 (1.7, 1.4–2) | 0.008 (1.4, 1.1–1.8) |
| Driver mutational status (type 1/like CALR reference) | <0.0001 | <0.0001 |
| JAK 2 | 0.0001 (2.6, 2–3.5) | 0.0001 (2.5, 1.8–3.6) |
| Type 2/like CALR | 0.001 (2.5, 1.4–4.5) | 0.02 (2.2, 1.1–4.3) |
| MPL | 0.01 (1.8, 1.1–3) | 0.0003 (2.7, 1.6–4.8) |
| Triple negative | 0.0001 (2.4, 1.6–3.6) | 0.0008 (2.2, 1.4–3.4) |
| Type 1/like CALR absent | <0.0001 (2.5, 1.9–3.4) | <0.0001 (2.5–1.7–3.5) |
| ASXL1–mutated | <0.0001 (2, 1.6–2.5) | <0.0001 (1.8, 1.4–2.3) |
| SRSF2-mutated | <0.0001 (2, 1.5–2.6) | 0.001 (1.7, 1.2–2.3) |
| DIPSS | <0.0001 | |
| High | 0.0001 (10, 7.3–14) | |
| Intermediate 2 | 0.0001 (6, 4.6–8.2) | |
| Intermediate-1 | 0.0001 (2.7, 2.0–3.6) | |
| Low | Reference | |
| DIPSS-plus | <0.0001 | |
| High | 0.0001 (10, 7.2–13.8) | |
| Intermediate 2 | 0.0001 (4.7, 3.3–6.3) | |
| Intermediate-1 | 0.0001 (2, 1.4–2.9) | |
| Low | Reference | |
| Revised cytogenetic riska | <0.0001 | <0.0001 |
| VHR | 0.0001 (3.8, 2.9–4.9) | 0.0001 (3.6, 2.3–5.8) |
| Unfavorable | 0.0001 (1.6, 1.4–2) | 0.0001 (2.4, 1.8–3.3) |
| Favorable | Reference | Reference |
The values in bold indicate a significant P value ( < 0.05)
aRevised cytogenetic risk stratification: “very high risk (VHR)”—single/multiple abnormalities of –7, i(17q), inv(3)/3q21, 12p−/12p11.2, 11q−/11q23, +21, or other autosomal trisomies, not including +8 / +9; “favorable”—normal karyotype or sole abnormalities of 13q−, + 9, 20q−, chromosome 1 translocation/duplication or sex chromosome abnormality including -Y; “unfavorable”—all other abnormalities (Tefferi et al. personal communication, 05 November 2017)